BioXcel Therapeutics, Inc. (NASDAQ:BTAI) on Wednesday released topline exploratory efficacy data from the SERENITY At-Home Pivotal Phase 3 safety trial, which demonstrated that BXCL501 had continued ...
Agitation is a neuropsychiatric symptom in patients with Alzheimer's disease (AD), the most common form of dementia. The prevalence of this symptom is about 40%-65% ...
Agitation can be one of the most troubling symptoms of Alzheimer’s disease. You’ve probably tried everything you could think of to bring calm to your loved one. Keep in mind the behavior is part of ...
Agitation caused by Alzheimer’s disease currently has one FDA-approved therapy, but that drug brings serious safety risks. An Axsome Therapeutics drug has mixed results from its latest slate of ...
Treatment with AXS-05, a combination of dextromethorphan and bupropion, demonstrated rapid, sustained, and clinically meaningful improvement in agitation related to Alzheimer's disease (AD) and was ...
Aug 27 (Reuters) - BioXcel Therapeutics (BTAI.O), opens new tab said on Wednesday it plans to seek expanded approval early next year for use of its agitation drug at home after it succeeded in a ...
Benzodiazepines like lorazepam can precipitate or worsen delirium, and are often avoided for patients with end-of-life delirium. Among cancer patients in a palliative care setting, those who received ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback